Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 124 Results

Title
Intervention Indication Therapeutic Area Year Actions
Selinexor in combination with low-dose dexamethasone for penta-refractory multiple myeloma Dexamethasone (dexamethasone sodium metasulfobenzoate) , Selinexor (KPT-330; Xpovio) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2018 View  |  Download
Synthetic hypericin (SGX301; VIMRxyn) for cutaneous T‐cell lymphoma, unspecified Hypericin (SGX301; HBP-347) Cutaneous T-cell lymphoma (CTCL) Haematological Cancer and Lymphomas 2017 View  |  Download
Tabelecleucel for Epstein-Barr Virus-associated lymphoproliferative disease following solid organ transplant Tabelecleucel (Tab-cel; ATA129) Post-transplant lymphoproliferative disease (PTLD) Haematological Cancer and Lymphomas 2019 View  |  Download
Tafasitamab in combination with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma Tafasitamab (MOR208; Monjuvi) Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2020 View  |  Download
Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm Tagraxofusp (Elzonris; SL-401) Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Haematological Cancer and Lymphomas 2018 View  |  Download
Talquetamab for previously treated relapsed or refractory multiple myeloma Talquetamab Multiple myeloma (MM) Haematological Cancer and Lymphomas 2022 View  |  Download
Teclistamab for previously treated relapsed or refractory multiple myeloma Teclistamab Multiple myeloma (MM) Haematological Cancer and Lymphomas 2022 View  |  Download
Teclistamab with daratumumab for previously treated relapsed or refractory multiple myeloma Daratumumab (Darzalex; JNJ-54767414) , Teclistamab Multiple myeloma (MM) Haematological Cancer and Lymphomas 2022 View  |  Download
Tisagenlecleucel for relapsed or refractory follicular lymphoma Tisagenlecleucel-T (Kymriah; CTL019) Follicular lymphoma Haematological Cancer and Lymphomas 2021 View  |  Download
Tisagenlecleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma – second line Tisagenlecleucel-T (Kymriah; CTL019) B-cell non-Hodgkin lymphoma Haematological Cancer and Lymphomas 2021 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications